391 related articles for article (PubMed ID: 18332901)
41. Treatment and prognosis of patients with paraplegia or quadriplegia because of metastatic spinal cord compression in prostate cancer.
Nagata M; Ueda T; Komiya A; Suzuki H; Akakura K; Ishihara M; Tobe T; Ichikawa T; Igarashi T; Ito H
Prostate Cancer Prostatic Dis; 2003; 6(2):169-73. PubMed ID: 12806378
[TBL] [Abstract][Full Text] [Related]
42. Genetic polymorphism in EGF is associated with prostate cancer aggressiveness and progression-free interval in androgen blockade-treated patients.
Teixeira AL; Ribeiro R; Cardoso D; Pinto D; Lobo F; Fraga A; Pina F; Calais-da-Silva F; Medeiros R
Clin Cancer Res; 2008 Jun; 14(11):3367-71. PubMed ID: 18519765
[TBL] [Abstract][Full Text] [Related]
43. Serum chromogranin A in monitoring metastatic prostate cancer patients.
Tarle M
Anticancer Res; 1999; 19(6C):5663-6. PubMed ID: 10697637
[TBL] [Abstract][Full Text] [Related]
44. NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model.
Diallo JS; Aldejmah A; Mouhim AF; Péant B; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F
Clin Cancer Res; 2007 Dec; 13(23):7044-52. PubMed ID: 18056181
[TBL] [Abstract][Full Text] [Related]
45. Prognostic significance of disseminated tumor cells in the bone marrow of prostate cancer patients treated with neoadjuvant hormone treatment.
Köllermann J; Weikert S; Schostak M; Kempkensteffen C; Kleinschmidt K; Rau T; Pantel K
J Clin Oncol; 2008 Oct; 26(30):4928-33. PubMed ID: 18794550
[TBL] [Abstract][Full Text] [Related]
46. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
47. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases.
Colombel M; Eaton CL; Hamdy F; Ricci E; van der Pluijm G; Cecchini M; Mege-Lechevallier F; Clezardin P; Thalmann G
Prostate; 2012 May; 72(7):713-20. PubMed ID: 21882211
[TBL] [Abstract][Full Text] [Related]
48. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480.
Humphrey PA; Halabi S; Picus J; Sanford B; Vogelzang NJ; Small EJ; Kantoff PW
Clin Genitourin Cancer; 2006 Mar; 4(4):269-74. PubMed ID: 16729910
[TBL] [Abstract][Full Text] [Related]
49. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.
Cabrespine A; Guy L; Gachon F; Curé H; Chollet P; Bay JO
J Urol; 2006 Apr; 175(4):1347-52. PubMed ID: 16515996
[TBL] [Abstract][Full Text] [Related]
50. Serum parathyroid hormone-related peptide is associated with systemic inflammation and adverse prognosis in gastroesophageal carcinoma.
Deans C; Wigmore S; Paterson-Brown S; Black J; Ross J; Fearon KC
Cancer; 2005 May; 103(9):1810-8. PubMed ID: 15800880
[TBL] [Abstract][Full Text] [Related]
51. Dose-escalated radiation therapy for intermediate-risk prostate cancer: patient selection for androgen deprivation therapy using percentage of positive cores.
Liauw SL; Fricano J; Correa D; Weichselbaum RR; Jani AB
Cancer; 2009 Apr; 115(8):1784-90. PubMed ID: 19208426
[TBL] [Abstract][Full Text] [Related]
52. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.
Nelson JB; Nabulsi AA; Vogelzang NJ; Breul J; Zonnenberg BA; Daliani DD; Schulman CC; Carducci MA
J Urol; 2003 Mar; 169(3):1143-9. PubMed ID: 12576870
[TBL] [Abstract][Full Text] [Related]
53. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
54. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007).
Nørgaard M; Jensen AØ; Jacobsen JB; Cetin K; Fryzek JP; Sørensen HT
J Urol; 2010 Jul; 184(1):162-7. PubMed ID: 20483155
[TBL] [Abstract][Full Text] [Related]
55. Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group.
Collette L; van Andel G; Bottomley A; Oosterhof GO; Albrecht W; de Reijke TM; Fossà SD
J Clin Oncol; 2004 Oct; 22(19):3877-85. PubMed ID: 15459209
[TBL] [Abstract][Full Text] [Related]
56. An immunohistochemical study of chromogranin A and human epidermal growth factor-2 expression using initial prostate biopsy specimens from patients with bone metastatic prostate cancer.
Yamada Y; Nakamura K; Aoki S; Taki T; Naruse K; Matsubara H; Tobiume M; Zennami K; Katsuda R; Honda N
BJU Int; 2007 Jan; 99(1):189-95. PubMed ID: 17034504
[TBL] [Abstract][Full Text] [Related]
57. Hypocalcemia due to avid calcium uptake by osteoblastic metastases of prostate cancer.
Szentirmai M; Constantinou C; Rainey JM; Loewenstein JE
West J Med; 1995 Dec; 163(6):577-8. PubMed ID: 8553652
[No Abstract] [Full Text] [Related]
58. Advanced but not localized prostate cancer is associated with increased oxidative stress.
Yossepowitch O; Pinchuk I; Gur U; Neumann A; Lichtenberg D; Baniel J
J Urol; 2007 Oct; 178(4 Pt 1):1238-43; discussion 1243-4. PubMed ID: 17698111
[TBL] [Abstract][Full Text] [Related]
59. Assessment of serum chromogranin-A as prognostic factor in high-risk prostate cancer.
Reis LO; Vieira LF; Zani EL; Denardi F; de Oliveira LC; Ferreira U
J Investig Med; 2010 Dec; 58(8):957-60. PubMed ID: 20818262
[TBL] [Abstract][Full Text] [Related]
60. [Role of biochemical indices as metastatic markers in patients with prostatic cancer invading skeleton].
Liubimova NV; Trapeznikova MF; Robins SP; Ognerubov SA; Kushlinskiĭ NE
Urologiia; 2000; (4):15-9. PubMed ID: 11186686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
